Novel Systems, Methods, And Compositions For The Glycosylation Of Cannabinoid Compounds
AssigneeTrait Biosciences, Inc.
InventorsTimothy Travers, Erick LeBrun
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the identification novel UDP-glucosyltransferases enzymes having specific activity towards cannabinoid compounds. The present invention further relates generally to the use of novel UGT enzymes having specific activity towards cannabinoid compounds to generate water-soluble cannabinoid glycoside compounds.
Claims86
A method comprising the step of:
- introducing a cannabinoid having at least one glycosylation site to a UDP-glucosyltransferases (UGT) having glycosylation activity towards the cannabinoid;
- glycosylating the cannabinoid forming a cannabinoid glycoside;
- and
- wherein said UGT comprises a UGT selected from the group consisting of:
- a UGT from the structural group Gram+UGTs, a UGT from the structural group GT-A UGTs, and a UGT from the structural group GT-B UGTs.
A system comprising:
- an in vivo, ex vivo or in vitro system comprising:
- a quantity of one or more cannabinoids each having at least one glycosylation site;
- a UDP-glucosyltransferases (UGT) having glycosylation activity towards said one or more cannabinoids wherein said UGT comprises a UGT selected from the group consisting of:
- a UGT from the structural group Gram+UGTs, a UGT from the structural group GT-A UGTs, and a UGT from the structural group GT-B UGTs;
- and
- a quantity of cannabinoid glycosides isolated from said in vivo, ex vivo or in vitro system.
A method comprising the step of:
- introducing a cannabinoid having at least one glycosylation site to a UDP-glucosyltransferases (UGT) having glycosylation activity towards said cannabinoid, wherein said UGT comprises a UGT having a GT-A fold consisting of a single domain with a seven-stranded β-sheet flanked on both sides of the sheet by a plurality of α-helices;
- and
- glycosylating the cannabinoid forming a cannabinoid glycoside.
A system comprising:
- an in vivo, ex vivo or in vitro system comprising:
- a quantity of one or more cannabinoids each having at least one glycosylation site;
- a UDP-glucosyltransferases (UGT) having glycosylation activity towards said cannabinoid, wherein said UGT comprises a UGT having a GT-A fold consisting of a single domain with a seven-stranded β-sheet flanked on both sides of the sheet by a plurality of α-helices;
- and
- a quantity of cannabinoid glycosides isolated from said in vivo, ex vivo or in vitro system.
A method comprising the step of:
- introducing a cannabinoid having at least one glycosylation site to a UDP-glucosyltransferases (UGT) having glycosylation activity towards said cannabinoid, wherein said UGT comprises a UGT having a GT-A fold consisting of a single domain with a seven-stranded β-sheet flanked on both sides of the sheet by a plurality of α-helices and also an additional tetratricopeptide repeat (TPR) motif that mediates oligomer assembly;
- and
- glycosylating the cannabinoid forming a cannabinoid glycoside.
A system comprising:
- an in vivo, ex vivo or in vitro system comprising:
- a quantity of one or more cannabinoids each having at least one glycosylation site;
- a UDP-glucosyltransferases (UGT) having glycosylation activity towards said cannabinoid, wherein said UGT comprises a UGT having a GT-A fold consisting of a single domain with a seven-stranded β-sheet flanked on both sides of the sheet by a plurality of α-helices and also an additional tetratricopeptide repeat (TPR) motif that mediates oligomer assembly;
- and
- a quantity of cannabinoid glycosides isolated from said in vivo, ex vivo or in vitro system.
A method comprising the step of:
- introducing a cannabinoid having at least one glycosylation site to a UDP-glucosyltransferases (UGT) having glycosylation activity towards said cannabinoid, wherein said UGT comprises a UGT having a GT-B fold consisting of two distinct N-terminal and C-terminal domains that both adopt Rossmann-like folds;
- and
- glycosylating the cannabinoid forming a cannabinoid glycoside.
A system comprising:
- an in vivo, ex vivo or in vitro system comprising:
- a quantity of one or more cannabinoids each having at least one glycosylation site;
- a UDP-glucosyltransferases (UGT) having glycosylation activity towards said cannabinoid, wherein said UGT comprises a UGT having a GT-B fold consisting of two distinct N-terminal and C-terminal domains that both adopt Rossmann-like folds;
- and
- a quantity of cannabinoid glycosides isolated from said in vivo, ex vivo or in vitro system.
An isolated nucleotide sequence operably linked to a promoter encoding at least one UDP-glucosyltransferases (UGT) having glycosylation activity towards at least one cannabinoid wherein said UGT comprises a UGT selected from the group of amino acid sequences consisting of:
- SEQ ID NOs. 1-9181, and a nucleotide sequence encoding an amino acid sequence having 90% sequence identity with SEQ ID NOs. 1-9181.
An isolated UDP-glucosyltransferases (UGT) having glycosylation activity towards THC, THCA, CBD and CBDA, wherein said UGT comprises a UGT having a GT-A fold consisting of a single domain with a seven-stranded β-sheet flanked on both sides of the sheet by several α-helices.
An isolated UDP-glucosyltransferases (UGT) having glycosylation activity towards THC, THCA, CBD and CBDA, wherein said UGT comprises a UGT having a GT-A fold consisting of a single domain with a seven-stranded β-sheet flanked on both sides of the sheet by several α-helices and also an additional tetratricopeptide repeat (TPR) motif that mediates the assembly of oligomers.
An isolated UGT having glycosylation activity towards THC, THCA, CBD and CBDA, wherein said UGT comprises a UGT having a GT-B fold consisting of two distinct N-terminal and C-terminal domains that both adopt Rossmann-like folds.
An isolated nucleotide sequence operably linked to a promoter encoding at least one UDP-glucosyltransferases (UGT) having glycosylation activity towards THC, THCA, CBD, or CBDA wherein said UGT comprises a UGT selected from the group of amino acid sequences consisting of:
- SEQ ID NOs. 1-9181, and a nucleotide sequence encoding an amino acid sequence having 90% sequence identity with SEQ ID NOs. 1-9181.
A cell expressing a heterologous nucleotide sequence operably linked to a promoter encoding at least one UDP-glucosyltransferases (UGT) having glycosylation activity towards at least one cannabinoid wherein said UGT comprises a UGT selected from the group of amino acid sequences consisting of:
- SEQ ID NOs. 1-9181, and a nucleotide sequence encoding an amino acid sequence having 90% sequence identity with SEQ ID NOs. 1-9181.
A cell expressing a heterologous nucleotide sequence operably linked to a promoter encoding at least one UDP-glucosyltransferases (UGT) having glycosylation activity towards THC, THCA, CBD and CBDA, wherein said UGT comprises a UGT having a GT-A fold consisting of a single domain with a seven-stranded β-sheet flanked on both sides of the sheet by several α-helices.
A cell expressing a heterologous nucleotide sequence operably linked to a promoter encoding at least one UDP-glucosyltransferases (UGT) having glycosylation activity towards THC, THCA, CBD and CBDA, wherein said UGT comprises a UGT having a GT-A fold consisting of a single domain with a seven-stranded β-sheet flanked on both sides of the sheet by several α-helices and also an additional tetratricopeptide repeat (TPR) motif that mediates the assembly of oligomers.
A cell expressing a heterologous nucleotide sequence operably linked to a promoter encoding at least one UDP-glucosyltransferases (UGT) having glycosylation activity towards THC, THCA, CBD and CBDA, wherein said UGT comprises a UGT having a GT-B fold consisting of two distinct N-terminal and C-terminal domains that both adopt Rossmann-like folds.
A cell expressing a heterologous nucleotide sequence operably linked to a promoter encoding at least one UDP-glucosyltransferases (UGT) having glycosylation activity towards THC, THCA, CBD, or CBDA wherein said UGT comprises a UGT selected from the group of amino acid sequences consisting of:
- SEQ ID NOs. 1-9181, and a nucleotide sequence encoding an amino acid sequence having 90% sequence identity with SEQ ID NOs. 1-9181.
Dependencies are inferred from the claim text.